

THE COMMISSIONER IS AUTHORIZED
TO CHARGE ANY DEFICIENCY IN THE
FEES FOR THIS PAPER TO DEPOSIT
ACCOUNT NO. 23-0975.

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE SEP 10 1999

In re application of

Koichi ISHIGURO et al.

Serial No. 09/142,613

Filed April 19, 1999



TECH CENTER 1600/2900

Docket No. 01416/OP551-PC-US

Group Art Unit 1645

Examiner S. Turner

#8 9/14/99 T. Gray
+ Box 1645

ANTI-PHOSPHORYLATED TAU PROTEIN
ANTIBODIES AND METHODS FOR
DETECTING ALZHEIMER'S DISEASE WITH
THE USE OF THE SAME

RESPONSE

Assistant Commissioner for Patents,
Washington, D.C. 20231

Sir:

Responsive to the Notice dated August 30, 1999, there is submitted herewith, in a separate Preliminary Amendment, a paper copy of a revised Sequence Listing for the above-identified application which has been prepared in accordance with the sequence rules under 37 C.F.R. 1.821-1.825. The Sequence Listing contains the identical sequences appearing in the original application papers. Thus, no new matter has been added.

There is also submitted herewith a copy of the Sequence Listing in computer readable form as required by 37 C.F.R. 1.821(e). The content of the paper and computer readable copies are the same.


A copy of the Notice is also attached as required.

In view of the foregoing, it is believed that each requirement set forth in the Notice has been satisfied, and that the application is now in compliance with the sequence rules under 37 C.F.R. 1.821-1.825. Accordingly, favorable examination on the merits is respectfully requested.

Respectfully submitted,

Koichi ISHIGURO et al.

By: _____


Lee Cheng
Registration No. 40,949
Attorney for Applicants

LC/dln
Washington, D.C.
Telephone (202) 721-8200
Facsimile (202) 721-8250
September 2, 1999



09/142613

Application No.:

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☒ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☒ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☒ 7. Other: See attached Raw Seq Listing Error Report

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE